Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Financing Activities (2016 - 2025)

Enanta Pharmaceuticals' Cash from Financing Activities history spans 14 years, with the latest figure at $64.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 1386.32% year-over-year to $64.1 million; the TTM value through Dec 2025 reached $42.5 million, up 268.25%, while the annual FY2025 figure was -$26.6 million, 3.65% up from the prior year.
  • Cash from Financing Activities reached $64.1 million in Q4 2025 per ENTA's latest filing, up from -$8.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $199.9 million in Q2 2023 to a low of -$8.3 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $11.5 million, with a median of $139000.0 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: soared 4751.33% in 2023, then tumbled 31269.57% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $9.6 million in 2021, then crashed by 96.88% to $301000.0 in 2022, then plummeted by 2541.86% to -$7.4 million in 2023, then soared by 32.16% to -$5.0 million in 2024, then surged by 1386.32% to $64.1 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Cash from Financing Activities are $64.1 million (Q4 2025), -$8.3 million (Q3 2025), and -$6.4 million (Q2 2025).